Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

11.9K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
11.9K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Cancer Prevention02:59

Cancer Prevention

6.1K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
6.1K
Mismatch Repair01:20

Mismatch Repair

4.8K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
4.8K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

8.8K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early <i>NOTCH1</i> mutation is positively selected but epistatically suppresses evolution of later esophageal squamous-cell carcinoma drivers.

bioRxiv : the preprint server for biology·2025
Same author

Glioma mutational signatures associated with haloalkane exposure are enriched in firefighters.

Cancer·2025
Same author

The Performance of Artificial Intelligence on a National Medical Licensing Examination—The Answers of Large Language Models to Text Questions.

Deutsches Arzteblatt international·2025
Same author

Estimation of Neutral Mutation Rates and Quantification of Somatic Variant Selection Using cancereffectsizeR.

Cancer research·2022
Same author

Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia.

Leukemia·2022
Same author

APOBEC mutagenesis and selection for NFE2L2 contribute to the origin of lung squamous-cell carcinoma.

Lung cancer (Amsterdam, Netherlands)·2022

Related Experiment Video

Updated: Jun 24, 2025

Mutagenesis and Functional Selection Protocols for Directed Evolution of Proteins in E. coli
09:01

Mutagenesis and Functional Selection Protocols for Directed Evolution of Proteins in E. coli

Published on: March 16, 2011

30.5K

Mutations, substitutions, and selection: Linking mutagenic processes to cancer using evolutionary theory.

Vincent L Cannataro1, Kira A Glasmacher1, Caralynn E Hampson1

  • 1Emmanuel College, 400 Fenway, Boston, MA 02115, United States of America.

Biochimica Et Biophysica Acta. Molecular Basis of Disease
|June 1, 2024
PubMed
Summary

Understanding cancer evolution requires analyzing molecular variations. This review covers tools to identify cancer drivers and mutagenesis mechanisms, crucial for preventing cancer deaths.

Keywords:
CancerEvolutionMutagenesisMutationMutational signaturesSelection

More Related Videos

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

2.3K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K

Related Experiment Videos

Last Updated: Jun 24, 2025

Mutagenesis and Functional Selection Protocols for Directed Evolution of Proteins in E. coli
09:01

Mutagenesis and Functional Selection Protocols for Directed Evolution of Proteins in E. coli

Published on: March 16, 2011

30.5K
Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

2.3K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K

Area of Science:

  • Oncology
  • Evolutionary Biology
  • Genomics

Background:

  • Cancers arise from accumulated molecular variations during evolutionary processes within tissues and tumors.
  • Identifying these variations is key to understanding tumorigenesis and the mechanisms driving mutagenesis.
  • Preventing premature cancer deaths relies on targeting cancer-driving variants and mitigating exogenous mutations.

Purpose of the Study:

  • To review existing tools for identifying molecular signatures and cancer drivers.
  • To explore methods for linking molecular signatures and cancer drivers.
  • To provide insights into preventing cancer through understanding its evolutionary basis.

Main Methods:

  • Literature review of computational and experimental tools.
  • Analysis of methods for detecting molecular signatures (mutational patterns).
  • Review of techniques for identifying driver mutations in cancer genomes.

Main Results:

  • A range of tools exists for characterizing molecular signatures and cancer drivers.
  • Methods are available to link mutational processes to specific driver alterations.
  • Integration of these metrics offers a comprehensive view of cancer evolution.

Conclusions:

  • Understanding cancer's evolutionary dynamics is critical for therapeutic strategies.
  • Tools for analyzing molecular signatures and cancer drivers are advancing.
  • Linking these analyses provides a pathway for novel cancer prevention and treatment approaches.